Detalles de la búsqueda
1.
Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2- early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2- trial.
Ann Oncol
; 34(6): 531-542, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37062416
2.
De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel.
Ann Oncol
; 28(11): 2768-2772, 2017 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28945833
3.
Corrigendum to "De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel": [Annals of Oncology 28 (2017) 2768-2772].
Ann Oncol
; 33(3): 355, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-35012798
4.
Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto).
Ann Oncol
; 25(12): 2363-2372, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-25223482
5.
Modulation of benzo[a]pyrene-induced morphological transformation of Syrian hamster embryo cells by butylated hydroxytoluene and butylated hydroxyanisole.
Cancer Lett
; 33(2): 189-98, 1986 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-3791190
6.
Enhancement and inhibition of benzo[a]pyrene-induced SOS function in E. coli by synthetic antioxidants.
Mutat Res
; 207(1): 7-11, 1988 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-3275888
7.
First evaluation of the Joint Clinical Registries of the Coordinating Tumor Center of Berlin.
Anticancer Res
; 31(8): 2657-60, 2011 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-21778319
Resultados
1 -
7
de 7
1
Próxima >
>>